This group of medications consists of blockers of several proteins and, to date,, the inhibitors of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3), were introduced into standards of care of numerous neoplasms, such as melanoma, non-small cell lung cancer, renal cell carcinoma, etc. [5]. This evidence concerns the gene PDCD1 and melanoma.